Daiichi Sankyo is proud to announce that its proprietary DXd ADC platform has been named the Best ADC Platform Technology at the 12th Annual World ADC Awards, held on November 5, 2025.

This prestigious recognition underscores Daiichi Sankyo’s industry-leading science and innovation in DXd ADC technology, which contributes to advancing new standards of care for patients with cancer worldwide.

In addition, the World ADC Awards introduced a renamed honor—The Toshinori Agatsuma Long Standing Contribution to the Field Award —in tribute to the late Dr. Toshinori Agatsuma, whose pioneering work in ADC research and development helped shape the trajectory of Daiichi Sankyo’s oncology portfolio.

Daiichi Sankyo remains dedicated to creating and delivering innovative medicines, leveraging its strengths in Science and Technology to contribute to the enrichment of quality of life around the world.

※World ADC Awards：An internationally recognized awards program that celebrates excellence in ADC research, clinical impact, and innovation. Winners are announced annually at the World ADC Summit.